Obviousness

As a senior US patent analyst, I have analyzed the potential obviousness of US patent 12502357 under 35 U.S.C. § 103, based on the previously supplied prior art references.

Obviousness Analysis under 35 U.S.C. § 103

Under 35 U.S.C. § 103, a patent claim is unpatentable if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). An obviousness analysis requires finding a suggestion or motivation to combine prior art elements with a reasonable expectation of success.

The PHOSITA for US patent 12502357 would be a pharmaceutical scientist or formulation chemist with experience in developing oral dosage forms, particularly for compounds with poor aqueous solubility.

1. The Core Invention and the Known Problem

The core invention of US 12502357 is a pharmaceutical composition comprising a solid amorphous dispersion of the drug enzalutamide and a concentration-enhancing polymer, such as hydroxypropylmethylcellulose acetate succinate (HPMCAS). The patent text demonstrates through extensive data (e.g., Tables 4.1, 4.2, 8.1) that this formulation overcomes the low aqueous solubility of crystalline enzalutamide, leading to significantly improved bioavailability.

The foundational prior art, US Patent 7,709,517, discloses the compound enzalutamide and its use for treating prostate cancer. A PHOSITA would recognize from the chemical structure and properties of enzalutamide that it is a poorly water-soluble compound, a common challenge in drug development that often leads to poor or variable oral bioavailability. Therefore, the problem to be solved—improving the bioavailability of enzalutamide—was readily apparent from the primary prior art.

2. Combination of Prior Art

The provided prior art list (US 7,709,517, US 2007/0004753, and US 7,611,630) is, by itself, insufficient to render the claims of US 12502357 obvious. While US '517 teaches the drug, it does not teach the solution of using an amorphous solid dispersion with a concentration-enhancing polymer.

However, a strong case for obviousness can be made by combining US 7,709,517 with another prior art reference that teaches the general applicability of amorphous solid dispersions for improving the bioavailability of poorly soluble drugs. By the priority date of US 12502357 (September 11, 2012), the technique of using polymers like HPMCAS to form amorphous solid dispersions was a well-established and widely discussed solution for this exact class of problem.

A hypothetical obviousness rejection would be constructed as follows:

• Primary Reference: US 7,709,517 teaches the compound enzalutamide and its use in treating prostate cancer. It also inherently presents the problem of formulating this poorly soluble compound for effective oral delivery.
• Secondary Reference(s): A patent or scientific publication existing before September 11, 2012, that teaches the use of concentration-enhancing polymers, specifically HPMCAS, to form amorphous solid dispersions of poorly soluble drugs via spray-drying or hot-melt extrusion to increase their solubility and oral bioavailability. This technology was widely known and frequently described in the pharmaceutical arts.

3. Motivation to Combine

A PHOSITA, presented with the promising therapeutic agent enzalutamide from US 7,709,517, would have been immediately confronted with its poor solubility. In seeking a solution, the PHOSITA would have surveyed known formulation strategies for bioavailability enhancement. The use of amorphous solid dispersions was a leading and well-documented approach for this class of compounds (BCS Class II/IV drugs).

The motivation to combine the teaching of US 7,709,517 with a secondary reference on amorphous dispersions would be the explicit goal of solving the drug's inherent solubility problem to create a viable oral pharmaceutical product. Applying this known formulation technology to the known drug enzalutamide would not be an inventive leap but rather the predictable application of a known solution to a known problem.

There would be a reasonable expectation of success. The secondary art would teach that this method is broadly applicable to poorly soluble compounds, providing a clear path for the PHOSITA to follow. While routine experimentation would be required to optimize the drug-to-polymer ratio and processing parameters for enzalutamide specifically, this optimization is not considered inventive. The extensive examples in US 12502357 detailing various drug loads (e.g., 25%, 40%, 60%, 80% enzalutamide) and polymers (HPMCAS, PVP-VA) represent this type of routine optimization.

Conclusion

While the provided prior art references alone do not render the claims obvious, the combination of US 7,709,517 with the general knowledge in the art regarding amorphous solid dispersions for bioavailability enhancement would form a strong prima facie case for the obviousness of the core claims of US 12502357. The invention appears to be the application of a known and successful formulation technique to a known compound to achieve a predictable and desired result.